Breaking News, Promotions & Moves

AMRI

AMRI has made a series of changes to its India operations and leadership team.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AMRI has made a series of changes to its India operations and leadership team, supporting the establishment of an integrated offering of chemical development and manufacturing services as part of an effort to increase efficiencies of the company’s global operations and to reduce costs.

Rajesh Shenoy, Ph.D. has been named managing director, India operations. Previously director for the company’s site in Hyderabad, India, Dr. Shenoy’s role has expanded to include large scale commercial manufacturing operations in Aurangabad, India. He assumed leadership for Hyderabad operations in 2005 as part of the AMRI team that established one of the company’s first sites outside of the U.S., and its first in India. Dr. Shenoy will report to Steven R. Hagen, Ph.D., AMRI vice president of pharmaceutical development and manufacturing.

Sivakumar Sivasubramanian has been named director, general operations to assume oversight for all general plant operations and engineering services for AMRI in India. Mr. Sivasubramanian joined AMRI in Hyderabad in 2005 as general manager, operations.

Sridhar Vaddeboina, Ph.D. has been named director of analytical services, India Operations. Dr. Vaddeboina most recently served as manager, analytical quality services for India operations, and will now lead all analytical and quality functions in India.

“We are pleased to announce the promotions of Drs. Shenoy and Vaddeboina and Mr. Sivasubramanian into these expanded leadership roles,” said AMRI Chairman, CEO and President Thomas E. D’Ambra, Ph.D. “Besides benefiting from their ability to achieve positive results as demonstrated by their efforts in establishing and growing our Hyderabad site, we believe that there will be significant synergies and collaborative benefits gained by combining leadership of the entire AMRI India footprint under one helm.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters